First Generic Tamiflu Approved in Time for Flu Season

Just in time for the 2016-2017 flu season, the FDA has approved the first generic version of oseltamivir phosphate (Tamiflu).

The generic oral capsules in 30 mg, 45 mg and 75 mg dosages from Natco Pharma are indicated for the treatment of influenza types A and B in patients 2 weeks and older who have had flu symptoms for no more than 48 hours. The drug is also used to prevent flu in patients 1 year and older.

Importantly, Tamiflu doesn’t take the place of receiving annual flu vaccination. It also doesn’t treat or prevent illness caused by infections other than the influenza virus, or prevent bacterial infections that may occur with the flu.

The FDA hasn’t yet determined whether Tamiflu is effective in patients who start treatment after 2 days of developing symptoms, or those who have weakened immune systems.

Last year, pharmacies across the country reported shortages of Tamiflu.